The long-term follow-up on local control of breast carcinoma treated by external beam irradiation plus iridium 192 implant

Abstract

Purpose/ObjectiveWe analyzed local recurrence and survival rate in breast cancer treated by radiotherapy alone with Pierquin technical after reclassified the stage according to the U.I.C.C. Tumor Classification System in 1997.Materials/MethodsFrom 1971 to 1983, 474 (39 T1, 325 T2, 65 T3) (UICC 1997) breast cancer were treated conservatively at Henri Mondor Hospital by an initial course of external irradiation (45 Gy, 25 fractions, 5 weeks) followed by interstitial iridium-192 implant for a further 37 Gy to the tumor. The mean age was 56 years old. Clinical positive nodes were 187 (36.2%) cases. 62 (9.7%) patients were received chemotherapy. The mean interval between external irradiation and Brachytherapy was 2.56 weeks (S.E. 0.11, range 0.5–23).ResultsEighty-nine local failures were observed at 9–361 months (mean 65 months). The actuarial probabilities (S.E.) of local control at 5, 10, 15 and 20 years were 0.87, 0.80, 0.76 and 0.72, respectively. The local control rate was 79%, 80% and 83 %( p = 0.87) for T1, T2 and T3, respectively. The mean and median distant metastasis was 73 months (ST error 4.33) ( 3–298 months) and 195 (ST error 6.64). At 5, 10, 15 and 20-year metastases-free survival rates, respectively, 75%, 60%, 52% and 48%. The metastases-free survival rate was 48%, 57% and 50 %( p = 0.16) for T1, T2 and T3 in this group, respectively. The mean and median disease-free survival was 106 months (ST error 4.16) (3–361 months) and 126 months (ST error 19), respectively. At 5, 10, 15 and 20-year disease-free survival rates, respectively, were 68%, 51%, 43% and 38 %. The disease-free survival rate was 41%, 48% and 43 %( p = 0.24) for T1, T2 and T3 in this group, respectively. The mean and median overall survivor was 136 months (ST error 4.22) (8–384 months) and 188 months (ST error 23.25). Overall survival rates at 5, 10, 15 and 20-year, respectively, were 80%, 65%, 51% and 47%. Overall survival rates of clinic positive nodes and negative, respectively, were 53% and 52%, (p = 0.03). Disease-free survival rates of clinic positive nodes and negative, respectively, were 43% and 38%, (p = 0.06). Distant metastasis-free survival rates of clinic positive nodes and negative, respectively, were 58% and 49%, (p = 0.01).ConclusionsAccording to the results of local recurrence, there were no significal difference in the size of tumor. There was a relationship between size of tumor (T3) and metastasis and disease-free survival rate. Clinical positive nodes were closed relationship with distant metastases and survival rate. Radiotherapy association chemotherapy was probably advantageous Purpose/ObjectiveWe analyzed local recurrence and survival rate in breast cancer treated by radiotherapy alone with Pierquin technical after reclassified the stage according to the U.I.C.C. Tumor Classification System in 1997. We analyzed local recurrence and survival rate in breast cancer treated by radiotherapy alone with Pierquin technical after reclassified the stage according to the U.I.C.C. Tumor Classification System in 1997. Materials/MethodsFrom 1971 to 1983, 474 (39 T1, 325 T2, 65 T3) (UICC 1997) breast cancer were treated conservatively at Henri Mondor Hospital by an initial course of external irradiation (45 Gy, 25 fractions, 5 weeks) followed by interstitial iridium-192 implant for a further 37 Gy to the tumor. The mean age was 56 years old. Clinical positive nodes were 187 (36.2%) cases. 62 (9.7%) patients were received chemotherapy. The mean interval between external irradiation and Brachytherapy was 2.56 weeks (S.E. 0.11, range 0.5–23). From 1971 to 1983, 474 (39 T1, 325 T2, 65 T3) (UICC 1997) breast cancer were treated conservatively at Henri Mondor Hospital by an initial course of external irradiation (45 Gy, 25 fractions, 5 weeks) followed by interstitial iridium-192 implant for a further 37 Gy to the tumor. The mean age was 56 years old. Clinical positive nodes were 187 (36.2%) cases. 62 (9.7%) patients were received chemotherapy. The mean interval between external irradiation and Brachytherapy was 2.56 weeks (S.E. 0.11, range 0.5–23). ResultsEighty-nine local failures were observed at 9–361 months (mean 65 months). The actuarial probabilities (S.E.) of local control at 5, 10, 15 and 20 years were 0.87, 0.80, 0.76 and 0.72, respectively. The local control rate was 79%, 80% and 83 %( p = 0.87) for T1, T2 and T3, respectively. The mean and median distant metastasis was 73 months (ST error 4.33) ( 3–298 months) and 195 (ST error 6.64). At 5, 10, 15 and 20-year metastases-free survival rates, respectively, 75%, 60%, 52% and 48%. The metastases-free survival rate was 48%, 57% and 50 %( p = 0.16) for T1, T2 and T3 in this group, respectively. The mean and median disease-free survival was 106 months (ST error 4.16) (3–361 months) and 126 months (ST error 19), respectively. At 5, 10, 15 and 20-year disease-free survival rates, respectively, were 68%, 51%, 43% and 38 %. The disease-free survival rate was 41%, 48% and 43 %( p = 0.24) for T1, T2 and T3 in this group, respectively. The mean and median overall survivor was 136 months (ST error 4.22) (8–384 months) and 188 months (ST error 23.25). Overall survival rates at 5, 10, 15 and 20-year, respectively, were 80%, 65%, 51% and 47%. Overall survival rates of clinic positive nodes and negative, respectively, were 53% and 52%, (p = 0.03). Disease-free survival rates of clinic positive nodes and negative, respectively, were 43% and 38%, (p = 0.06). Distant metastasis-free survival rates of clinic positive nodes and negative, respectively, were 58% and 49%, (p = 0.01). Eighty-nine local failures were observed at 9–361 months (mean 65 months). The actuarial probabilities (S.E.) of local control at 5, 10, 15 and 20 years were 0.87, 0.80, 0.76 and 0.72, respectively. The local control rate was 79%, 80% and 83 %( p = 0.87) for T1, T2 and T3, respectively. The mean and median distant metastasis was 73 months (ST error 4.33) ( 3–298 months) and 195 (ST error 6.64). At 5, 10, 15 and 20-year metastases-free survival rates, respectively, 75%, 60%, 52% and 48%. The metastases-free survival rate was 48%, 57% and 50 %( p = 0.16) for T1, T2 and T3 in this group, respectively. The mean and median disease-free survival was 106 months (ST error 4.16) (3–361 months) and 126 months (ST error 19), respectively. At 5, 10, 15 and 20-year disease-free survival rates, respectively, were 68%, 51%, 43% and 38 %. The disease-free survival rate was 41%, 48% and 43 %( p = 0.24) for T1, T2 and T3 in this group, respectively. The mean and median overall survivor was 136 months (ST error 4.22) (8–384 months) and 188 months (ST error 23.25). Overall survival rates at 5, 10, 15 and 20-year, respectively, were 80%, 65%, 51% and 47%. Overall survival rates of clinic positive nodes and negative, respectively, were 53% and 52%, (p = 0.03). Disease-free survival rates of clinic positive nodes and negative, respectively, were 43% and 38%, (p = 0.06). Distant metastasis-free survival rates of clinic positive nodes and negative, respectively, were 58% and 49%, (p = 0.01). ConclusionsAccording to the results of local recurrence, there were no significal difference in the size of tumor. There was a relationship between size of tumor (T3) and metastasis and disease-free survival rate. Clinical positive nodes were closed relationship with distant metastases and survival rate. Radiotherapy association chemotherapy was probably advantageous According to the results of local recurrence, there were no significal difference in the size of tumor. There was a relationship between size of tumor (T3) and metastasis and disease-free survival rate. Clinical positive nodes were closed relationship with distant metastases and survival rate. Radiotherapy association chemotherapy was probably advantageous